ReviewJournal of clinical medicine2023
The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Low-dose atropine for myopia progression in children: a 2017-2024 systematic review and meta-analysis of randomized placebo-controlled trials.Frontiers in medicine · 2026Pooled it
- Light Therapy for Myopia Prevention and Control: A Systematic Review on Effectiveness, Safety, and Implementation.Translational vision science & technology · 2024Pooled it
- Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.European journal of ophthalmology · 2024Guideline
- Impact of wearing dual-focus soft contact lenses on myopia progression: a one-year randomized clinical trial in Chinese school-age children.BMC ophthalmology · 2024Trial
- The efficiency of 0.01% topical atropine on the myopia prevention in low refractive error population with different refractive errors: a retrospective cohort study.BMC ophthalmology · 2026Article
- Atropine Eye Drops in Childhood Myopia Control: A Review.International journal of medical sciences · 2026Review
- The Daily and Two-Day Usage of Low-Dose Atropine on Myopic Control in a Low-Myopia Population.Journal of clinical medicine · 2025Article
- Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study.Journal of clinical medicine · 2024Article
- Retardation of myopia by atropine regimes.International journal of ophthalmology · 2024Review
- Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering risk-benefit ratio and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability to atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients complains and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving less side effects compared to 0.5% concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.